BiVictriX Therapeutics Plc (BVX.L) Research

BiVictriX Therapeutics Plc is a United Kingdom-based biotechnology firm dedicated to pioneering innovative treatments for cancer. The company's core technology involves its distinctive Bi-Cygni therapeutics, which are engineered to precisely identify and combat specific cancer types. Their foremost development program, BVX001, is currently being advanced to address acute myeloid leukaemia. Established in 2016 as BiVictriX Plc, the organization officially adopted its present name, BiVictriX Therapeutics Plc, in August 2021. Its corporate headquarters are located in Macclesfield, United Kingdom.

Market snapshot

Symbol
BVX.L
Price
$10.00
Day change
+17.65%
Market cap
$8.3M
P/E ratio
-2.85x
52-week range
0.0-14.0
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Advanced Oncotherapy plc (AVO.L)
  • Celadon Pharmaceuticals Plc (CEL.L)
  • Cambridge Nutritional Sciences plc (CNSL.L)
  • Destiny Pharma plc (DEST.L)
  • Induction Healthcare Group PLC (INHC.L)
  • MGC Pharmaceuticals Limited (MXC.L)
  • NetScientific plc (NSCI.L)
  • ReNeuron Group plc (RENE.L)

Open BiVictriX Therapeutics Plc (BVX.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.